Skip to main content
. 2020 Aug 22;12(9):2378. doi: 10.3390/cancers12092378

Figure 4.

Figure 4

Cell survival in response to cisplatin or 5-fluorouracil (5-FU) in MKN45 and GP202 cells. Percentage cell survival of CD44v6 expressing cells (Scramble) vs. CD44v6 KD cells and Scramble vs. exon-v6 depleted cells (O26, O15, O25) to cisplatin (represented in black) and 5-FU (represented in grey) treatment analyzed by Presto Blue (PB) and Sulforhodamine B (SRB) assays, after 48 h and clonogenic assay, after 10 days. The concentrations used in PB and SRB assays were: 2.5 µM (MKN45) and 20 µM (GP202) of cisplatin and 5 µM (MKN45 and GP202) of 5-FU. The concentrations used for the clonogenic assay were: 0.5 µM (MKN45 and GP202) for cisplatin and 2.5 µM (MKN45) and 2 µM (GP202) for 5-FU. Results represent the mean + SD of three independent experiments. Statistically significant results were determined by two-way ANOVA with Tukey’s Post Hoc Test for multiple comparison analysis (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). Src–Scramble; v6 KD–CD44v6 Knockdown; PB–PrestoBlue; SRB–Sulforhodamine B; Clono–Clonogenic; KD–Knockdown.